**LIST OF FIGURES:**

<table>
<thead>
<tr>
<th>Fig. No.</th>
<th>Title</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>Schematic Representation of the three main Methods of Preparations of Tablets</td>
<td>16</td>
</tr>
<tr>
<td>02</td>
<td>Different Configurations of Roller Compactor</td>
<td>19</td>
</tr>
<tr>
<td>03</td>
<td>&quot;V&quot; Blender</td>
<td>21</td>
</tr>
<tr>
<td>04</td>
<td>Planetary mixer</td>
<td>22</td>
</tr>
<tr>
<td>05</td>
<td>High-Shear Mixer Granulator</td>
<td>23</td>
</tr>
<tr>
<td>06</td>
<td>Continuous Wet Granulation Process</td>
<td>24</td>
</tr>
<tr>
<td>07</td>
<td>An overview of parts of body associated with pharmacotherapies for obesity</td>
<td>27</td>
</tr>
<tr>
<td>08</td>
<td>The proposed flow chart of pharmacotherapy for the management of obesity</td>
<td>28</td>
</tr>
<tr>
<td>09</td>
<td>Energy Intake and Energy Expenditure Balance</td>
<td>31</td>
</tr>
<tr>
<td>10</td>
<td>Model of medications recommended for the Obesity, Depression and BED</td>
<td>34</td>
</tr>
<tr>
<td>11</td>
<td>Schematic diagram of the basic steps involved in the production and disintegration of tablet</td>
<td>42</td>
</tr>
<tr>
<td>12</td>
<td>Virtual diagram of the oral absorption following oral solid dosage form</td>
<td>43</td>
</tr>
<tr>
<td>13</td>
<td>Fast Disintegrating Tablets Disintegrating image</td>
<td>44</td>
</tr>
<tr>
<td>14</td>
<td>Mini-Tablets prepared for the project</td>
<td>45</td>
</tr>
<tr>
<td>15</td>
<td>A virtual image of microparticles and mini-tablets compressed into a tablet</td>
<td>46</td>
</tr>
<tr>
<td>16</td>
<td>Virtual Model figure of Compression Coated Tablet</td>
<td>47</td>
</tr>
<tr>
<td>17</td>
<td>Schematic representation of compatibility studies</td>
<td>114</td>
</tr>
<tr>
<td>18</td>
<td>Orodispersible Mini-Tablets of ORL</td>
<td>125</td>
</tr>
<tr>
<td>19</td>
<td>FTIR spectrum of ORL (Pure drug)</td>
<td>136</td>
</tr>
</tbody>
</table>
20 IR Spectra of ORL with Excipients
21 X-ray Diffractograms of (a) ORL Pure (b) ORL-β-CD (1:2) complex
22 UV-spectrum of ORL
23 Standard graph for ORL in Methanol
24 Standard Graph of ORL in Water + 3% SLS
25 HPLC Chromatograph of ORL
26 ORL Standard graph by HPLC
27 Solubility study results of pure ORL and ORL-βCD Ph. Mix and complex
28 ORL ORMTs Dissolution profile of formulations ORMT (1-9)
29 HPLC Chromatograph of (ORMT-9) and Marketed ORL capsule
30 Dissolution profile of Optimized formulation (ORMT-9) and Marketed ORL capsule.
31 Taste Evaluation of Optimized Formulation (ORMT-9), on a scale of five
32 Zero order release kinetics of Optimized ORL ORMT-9 and marketed formulation.
33 First order release kinetics of Optimized ORL ORMT-9 and marketed formulation.
34 Higuchi release kinetics of Optimized ORL ORMT-9 and marketed formulation.
35 Hixson-Crowell release kinetics of Optimized ORL ORMT-9 and marketed formulation.
36 Schematic representation of compatibility studies
37 a) Mini-Tablets of ORL b) ORL-BPN Combination Chewable Mini tablets-In-Tablet
38 FTIR spectrum of ORL (Pure drug)
39 FTIR spectrum of ORL with excipients
40 FTIR spectrum of BPN Hcl (Pure drug)
41 FTIR spectrum of BPN Hcl with Excipients  178
42 FTIR spectrum of Combination ORL and BPN  178
43 UV-spectrum of ORL  179
44 Standard graph for ORL in Methanol  181
45 Standard Graph of ORL in Water + 3% SLS  182
46 UV Spectrum of BPN Hcl  182
47 Standard graph or BPN Hcl in Water  183
48 Standard graph or BPN Hcl in Water + 3% SLS  184
49 HPLC Chromatograph for ORL and BPN Hcl  185
50 Linearity graph for ORL & BPN Hcl  186
51 ORL Standard graph by HPLC  187
52 BPN Hcl Standard graph by HPLC  189
53 Intra-Day Precision of BPN Hcl & ORL. (10µg/ml & 100µg/ml)  190
54 Intra-Day Precision of BPN Hcl & ORL. (8µg/ml & 80µg/ml)  191
55 Inter-Day Precision of ORL (100µg/ml) & BPN Hcl (10µg/ml)  192
56 System Suitability Parameters  193
57 Robustness data peaks by varying the flow  194
58 Robustness of BPN Hcl & ORL by varying the PH  195
59 SEM image of BPN Microparticles  197
60 Dissolution profile of OBTT-1  201
61 Dissolution profile of OBTT-2  201
62 Dissolution profile of OBTT-3  202
63 Dissolution profile of OBTT-4  202
64 Dissolution profile of OBTT-5  203
65 Dissolution profile of OBTT-6  203
90 Precision of VNFHcl & ORL 246
91 Precision of ORL (120µg/ml) & VNFHcl (12µg/ml) 246
92 System Suitability Parameters 247
93 Robustness data peaks by varying the flow 248
94 Solubility of ORL-Pure, ORL-βCD (PM) and ORL-βCD-Complex 250
95 IR Spectra of Pure VNF and VNF Microparticles 251
96 SEM of VNF Microparticles 252
97 Disintegrating Pattern of ORL Inner core Optimized formulation 255
98 Drug Release Profile of Six Formulations of ORL Inner core (ORC 1-6) 256
99 Drug Release Profile of Six Formulations of VNF Outer coat layers (VCL 1-6) 258
100 Drug Release Profile of Optimized (OPCT); ORC-2 Core press coated with VLC-5 Outer layers 259
101 First order release kinetics of OPCT 260
102 Zero order release kinetics of OPCT 261
103 Higuchi release kinetics of OPCT 261
104 Taste Evaluation of Optimized Formulation (OPCT) 262